Modern Fixed Combinations in the Correction of Arterial Hypertension and Dyslipidemia

Based on a clinical case report, the article shows the individual selection of effective therapy for a patient with arterial hypertension and dyslipidemia. Taking into account the risk factors for cardiovascular diseases, Equamer® was selected as a fixed combination of amlodipine + lisinopril + rosuvastatin capsules 10 mg+20 mg+10 mg (Gedeon Richter Plc, Budapest, Hungary). In the patient with hypertension, ischemic heart disease was verified, and stenting of the anterior descending artery was performed. According to the clinical guidelines, when arterial hypertension is associated with ischemic heart disease, the drug therapy of choice should be a combination of dihydropyridine slow calcium channel blockers with an angiotensin-converting enzyme inhibitor. The fixed triple combination of amlodipine, lisinopril, and rosuvastatin is one of the most appropriate in this clinical situation; this combination targets the two major risk factors for cardiovascular diseases, arterial hypertension and dyslipidemia.

1. European Heart Network. Early detection of cardiovascular disease – an update from the European Heart Network – 2020. Av. at: https://ehnheart.org/wp-content/uploads/2023/08/EHN_CVD_Risk_Assessment_Programmes_Jan2021.pdf

2. Josipović J, Brčić K. Triple Combination, Two Diseases, and a Single Tablet. Cardiologia Croatica. 2023;18(5–6):188–92. DOI: 10.15836/ccar2023.188

3. World Health Organisation. Cardiovascular diseases (CVDs). [Internet] Available at: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)

4. Wilkins E, Wilson L, Wickramasinghe K, Bhatnagar P, Leal J, LuengoFernandez R et al. European cardiovascular disease statistics 2017 edition. European Heart Network, Brussels. Av at: http://www.ehnheart. org/images/CVD-statistics-report-August-2017.pdf

5. Coca A, Kreutz R, Manolis AJ, Mancia G. A practical approach to switch from a multiple pill therapeutic strategy to a polypill-based strategy for cardiovascular prevention in patients with hypertension. Journal of Hypertension. 2020;38(10):1890–8. DOI: 10.1097/HJH.0000000000002464

6. Agnello F, Capodanno D. Anti-inflammatory strategies for atherosclerotic artery disease. Expert Opinion on Drug Safety. 2022;21(5):661– 72. DOI: 10.1080/14740338.2022.2036717

7. Agnello F, Finocchiaro S, Laudani C, Legnazzi M, Mauro MS, Rochira C et al. A review of polypills for the prevention of atherosclerotic cardiovascular disease. American Heart Journal. 2023;266:74–85. DOI: 10.1016/j.ahj.2023.08.012

8. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Journal of Hypertension. 2018;36(10):1953–2041. DOI: 10.1097/HJH.0000000000001940

9. Chazova I.E., Zhernakova Yu.V. Clinical guidelines Diagnosis and treatment of arterial hypertension. Systemic Hypertension. 2019;16(1):6–31. DOI: 10.26442/2075082X.2019.1.190179

10. Khatib R, McKee M, Shannon H, Chow C, Rangarajan S, Teo K et al. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and lowincome countries: an analysis of the PURE study data. The Lancet. 2016;387(10013):61–9. DOI: 10.1016/S0140-6736(15)00469-9

11. Bubnova M.G., Ilchenko M.Yu., Lebedev P.A. Statins in the primary prevention of cardiovascular disease. Rosuvastatin capabilities. CardioSomatics. 2021;12(2):110–8. DOI: 10.26442//22217185.2021.2.200859

12. Choudhary A, Rawat U, Kumar P, Mittal P. Pleotropic effects of statins: the dilemma of wider utilization of statin. The Egyptian Heart Journal. 2023;75(1):1. DOI: 10.1186/s43044-023-00327-8

13. Cushman WC, Goff DC. More HOPE for Prevention with Statins. New England Journal of Medicine. 2016;374(21):2085–7. DOI: 10.1056/NEJMe1603504

14. Arutiunov A.G., Dragunov D.O., Sokolova A.V. Triple drug combinations in cardiology. Consilium Medicum. 2018;20(10):72–8. DOI: 10.26442/2075-1753_2018.10.72-78

15. Karpov Yu.A. Triple combination of antihypertensive and lipid–lowering drugs is an effective reduction in the risk of cardiovascular complications in patients with arterial hypertension. Russian Medical Journal. 2015;23(27):1580–3.

16. Karpov Yu.A. Study TRIUMVIRATE: Reducing the Risk of Cardiovascular Events in Hypertensive Patients Using Triple Combination Antihypertensive and Lipid-Lowering Drugs. Kardiologiia. 2015;55(9):10–5. DOI: 10.18565/cardio.2015.9.10-15

17. Kónyi A, Sárszegi Z, Hild G, Gaszner B. Safety and effectiveness of combined antihypertensive and cholesterol-lowering therapy in high-/very high-risk patients. Journal of Comparative Effectiveness Research. 2016;5(4):355–64. DOI: 10.2217/cer-2016-0003

18. Blankova Z.N., Aslanyan N.S., Smolianinova N.G., Ageev F.T. Treatment of patients with high cardiovascular risk: a modern view on combined therapy. Systemic Hypertension. 2017;14(1):12–6.

19. Blankova Z.N., Aslanyan N.S. The effect of combined therapy on the properties of the vessel wall in patients at high risk of cardiovascular complications. Systemic Hypertension. 2017;14(2):51–5. DOI: 10.26442/2075-082X_14.2.51-55

20. Nedogoda S.V. First polytablet: fixed-dose combination of angiotensin-converting enzyme, calcium antagonist, and statin. Doctor. Ru. 2016;11(128):42–8.

21. Russian Society of Cardiology. Clinical recommendations. Arterial hypertension in adults. 2020. Av. at: https://www.scardio.ru/content/Guidelines/2020/Clinic_rek_AG_2020_unlocked.pdf

22. Ministry of Health of Russian Federation. Clinical recommendations. Stable coronary heart disease. 2020. Av. at: https://www.scardio.ru/content/Guidelines/2020/Clinic_rekom_IBS-unlocked.pdf